Abbott Laboratories $ABT Shares Purchased by Mariner LLC

Mariner LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 40.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,893,420 shares of the healthcare product maker’s stock after purchasing an additional 544,866 shares during the quarter. Mariner LLC owned about 0.11% of Abbott Laboratories worth $253,596,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC grew its position in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC raised its holdings in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the period. United Bank lifted its stake in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares in the last quarter. Foundations Investment Advisors LLC grew its holdings in shares of Abbott Laboratories by 3.6% during the 2nd quarter. Foundations Investment Advisors LLC now owns 10,841 shares of the healthcare product maker’s stock worth $1,475,000 after purchasing an additional 377 shares during the period. Finally, Tortoise Investment Management LLC increased its position in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.8%

ABT stock opened at $109.93 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The firm has a 50 day simple moving average of $114.25 and a 200-day simple moving average of $123.65. The company has a market capitalization of $191.03 billion, a P/E ratio of 29.55, a PEG ratio of 1.72 and a beta of 0.74. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the transaction, the executive vice president directly owned 38,573 shares in the company, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 over the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on ABT shares. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Evercore reduced their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.